Arcutis Biotherapeutics Inc. (ARQT) Income Statement Analysis - Revenue, Earnings & Profitability Metrics - Stocknear
Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Start Trial

    Arcutis Biotherapeutics I...

    NASDAQ: ARQT · Real-Time Price · USD
    17.65
    0.92 (5.50%)
    At close: Sep 26, 2025, 1:13 PM

    Arcutis Biotherapeutics Income Statement

    Financials in USD. Fiscal year is January - December.

    undefined peaked at n/a in undefined and hit its lowest at n/a in undefined. Over the past five years, it has declined by undefined%.

    Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
    Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
    Revenue
    		 196.54M 59.61M 3.69M n/a
    Cost of Revenue
    		 19.13M 4.99M 754K 763K
    Gross Profit
    		 177.41M 54.62M 2.93M -763K
    Operating Income
    		 -128.4M -241.1M -301.63M -206.53M
    Interest Income
    		 n/a n/a n/a 173K
    Pretax Income
    		 -139.39M -259.03M -311.46M -206.36M
    Net Income
    		 -140.04M -262.14M -311.46M -206.36M
    Selling & General & Admin
    		 229.39M 185.15M 122.12M 60.97M
    Research & Development
    		 76.42M 110.58M 182.44M 145.56M
    Other Expenses
    		 n/a n/a n/a 173K
    Operating Expenses
    		 305.81M 295.72M 304.56M 206.53M
    Interest Expense
    		 27.17M 29.71M 15.65M n/a
    Selling & Marketing Expenses
    		 n/a n/a n/a n/a
    Cost & Expenses
    		 324.94M 300.71M 305.31M 206.53M
    Income Tax Expense
    		 647K 3.11M n/a -454K
    Shares Outstanding (Basic)
    		 120.96M 69.31M 55.03M 49.41M
    Shares Outstanding (Diluted)
    		 120.96M 69.31M 55.03M 49.41M
    EPS (Basic)
    		 -1.16 -3.78 -5.66 -4.17
    EPS (Diluted)
    		 -1.16 -3.78 -5.66 -4.17
    EBITDA
    		 -109.63M -227.43M -294.55M -205.59M
    EBIT
    		 -112.22M -229.31M -295.81M -206.36M
    Depreciation & Amortization
    		 2.6M 1.88M 1.25M 763K

    Add to Watchlist